1. Effect of imipramine on memory, adult neurogenesis, neuroinflammation, and mitochondrial biogenesis in a rat model of alzheimer's disease.
- Author
-
Hasanabadi AJ, Beirami E, Kamaei M, and Esfahani DE
- Subjects
- Animals, Male, Rats, Doublecortin Protein, Neuroinflammatory Diseases drug therapy, Memory drug effects, Brain-Derived Neurotrophic Factor metabolism, Memory Disorders drug therapy, Neuroprotective Agents pharmacology, Antidepressive Agents, Tricyclic pharmacology, Glial Cell Line-Derived Neurotrophic Factor metabolism, Glial Cell Line-Derived Neurotrophic Factor genetics, Cytokines metabolism, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Rats, Wistar, Neurogenesis drug effects, Imipramine pharmacology, Organelle Biogenesis, Disease Models, Animal, Hippocampus drug effects, Hippocampus metabolism, Streptozocin
- Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by cognitive decline and memory loss. Imipramine, a tricyclic antidepressant, has potent anti-inflammatory and antioxidant properties in the central nervous system. The aim of this study was to investigate the neuroprotective effects of imipramine on streptozotocin (STZ)-induced memory impairment. Male Wistar rats received an intracerebroventricular injection of STZ (3 mg/kg, 3 μl/ventricle) using the stereotaxic apparatus. The Morris water maze and passive avoidance tests were used to evaluate cognitive functions. 24 h after the STZ injection, imipramine was administered intraperitoneally at doses of 10 or 20 mg/kg for 14 consecutive days. The mRNA and protein levels of neurotrophic factors (BDNF and GDNF) and pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) were measured in the hippocampus using real-time PCR and ELISA techniques, respectively. In addition, real-time PCR was used to evaluate the mRNA levels of markers associated with neurogenesis (Nestin, DCX, and Ki67) and mitochondrial biogenesis (PGC-1α, NRF-1, and TFAM). The results showed that imipramine, especially at a dose of 20 mg/kg, effectively improved STZ-induced memory impairment. This improvement was associated with an increase in neurogenesis and neurotrophic factors and a decrease in neuroinflammation and mitochondrial biogenesis dysfunction. Based on these results, imipramine appears to be a promising therapeutic option for improving cognitive functions in neurodegenerative diseases such as AD., Competing Interests: Declarations of interest none., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF